ALAS1 · GalNAc, SC
Givosiran (Givlaari)
An approved siRNA therapeutic silencing ALAS1, indicated for Acute hepatic porphyria. This page lists what the siRNA Atlas corpus holds on Givosiran and links to each primary document.
Identity
- Generic name
- Givosiran
- Brand name
- Givlaari
- Molecular target
- ALAS1
- Indication
- Acute hepatic porphyria
- Delivery
- GalNAc, SC
- FDA application
- NDA 212194
- Regulatory coverage
- FDA and EMA
Source documents in the corpus (4)
- FDAFDA prescribing information (current label)
- FDAFDA review
- EMAEMA public assessment report (EPAR)
- EMAEMA product information (SmPC)
Every answer about Givosiran is drawn from these documents and the indexed literature, and cites the passage it used. Tables inside them are preserved, so numeric dosing, exposure and toxicology values stay searchable.
Ask the corpus about Givosiran
- →What is the approved dose and dosing interval of givosiran (Givlaari)?
- →Describe the clinical pharmacology and ADME of givosiran.
- →What did the regulatory reviews conclude about the nonclinical safety of givosiran?
- →Summarise the pivotal trial evidence for givosiran.
- →How does givosiran silence ALAS1, and how long does the effect last?
Other approved siRNA therapeutics
Information here is drawn from public regulatory records for reference and research. It is not medical advice — verify any clinical or regulatory decision against the current label and assessment report linked above.